www.HigherMedicine.Bio
Higher Medicine is advancing clinics-ready small molecules for pediatric and neurodegenerative disorders, starting with Kabuki syndrome and Friedreich’s ataxia. Our lead programs—an LSD1 inhibitor and a p38 MAP kinase inhibitor—are supported by substantial safety and clinical data, enabling a de-risked entry into Phase 2a trials by 2026. With $200K raised and $2.1M in soft commitments, we’re closing a $2M pre-seed round to complete IND-enabling steps. Backed by top-tier advisors and collaborators at Johns Hopkins and UPenn, we offer a capital-efficient path to near-term proof-of-concept data and long-term impact across autism, Alzheimer’s, and health span extension.
Company Details
- Employees
- 5
- Founded
- 2024
- Address
- Maryland / Delaware, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- HQ
- Maryland / Delaware
Higher Medicine Questions
Higher Medicine's LinkedIn profile is https://www.linkedin.com/company/highermedicine
Higher Medicine has
5 employees.
View email and phone details for 5
employees at Higher Medicine.
Higher Medicine's industry is
Biotechnology Research
Higher Medicine's top competitors are
Cornerstone Genomics,
Quneup®,
Ajaya Bio,
Trevarx Biomedical, Inc.,
Bound Therapeutics,
Valfard Therapeutics,
Biolattice,
Elixirgen Therapeutics, Inc.,
Drs.linq,
Cerespectus™.
Higher Medicine's categories are Biotechnology Research
Higher Medicine's founding year is 2024
